Trials / Not Yet Recruiting
Not Yet RecruitingNCT07110194
Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2825 Injection (Subcutaneous Injection) | TQB2825 is a Cluster of Differentiation 3 × Cluster of Differentiation 20 (CD3×CD20) dual antibody, which can simultaneously target the CD20 on tumor cells and the CD3 on T cells. It can induce T cell activation, proliferation and cytokine release, and effectively target and kill tumor cells. |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2026-03-01
- Completion
- 2027-12-01
- First posted
- 2025-08-07
- Last updated
- 2025-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07110194. Inclusion in this directory is not an endorsement.